text: Selegiline raises the availability of this compound by selectively inhibiting MAO-B. This compound's second G protein-coupled receptor, which inhibits adenylyl cyclase, is targeted by many antipsychotic drugs.
full_question: Selegiline raises the availability of this compound by selectively inhibiting MAO-B. This compound's second G protein-coupled receptor, which inhibits adenylyl cyclase, is targeted by many antipsychotic drugs. This compound's beta-hydroxylase catalyzes its transformation into norepinephrine. The ventral tegmental area contains the largest group of neurons releasing this neurotransmitter in the brain. A chiral precursor to this compound with (*) L-configuration is used to treat a disease in which neurons releasing it in the substantia nigra die, leading to tremors and a slow, shuffling gait. For 10 points, name this neurotransmitter involved in pleasure-reward pathways in the brain, whose levels fall in Parkinson's disease.
first_sentence: Selegiline raises the availability of this compound by selectively inhibiting MAO-B. This compound's second G protein-coupled receptor, which inhibits adenylyl cyclase, is targeted by many antipsychotic drugs.
raw_answer: Dopamine [or 3,4-dihydroxyphenethylamine] 